January 31, 2006 -- Sepracor led biotech higher on Tuesday, following announcement of strong Q4 and full-year 2005 results, largely due to new sleep medicine Lunestra; Acadia Pharma was the best percentage gainer after being touted on TV; SGX Pharma, which missed its IPO debut last week, cut the IPO price range for the second time; Canadian biotech Cangene received FDA approval for its hepatitis B immune globulin; BioMarin announced European approval of Naglazyme; CombinatoRX signed a partnership deal with Fovea Pharma of France; and Sunesis Pharma moved an anti-cancer drug into Phase I trials. The Centient Biotech 200™ gained 28 points to end at 3952.52, a rise of .72%. More details...
